Procedures for HPLC peptide map analysis of recombinant human granulocyte colony stimulating factor include reduction and S-carboxymethylation of the denatured protein, as well as protease digestion with Staphyloccus aureus endoproteinase Glu-C followed by reverse-phase liquid chromatographic separations. Under nonoptimized experimental conditions analytical problems including methionine modification during carboxymethylation, as well as generation of large, insoluble fragments and nonspecific cleavages during proteolytic digestion, occurred. These problems have complicated the analysis of peptide digests and affected the performance of HPLC columns. This report describes the elimination of these problems by optimizing peptide mapping procedures. We found that mild reduction and alkylation conditions can prevent methionine modification, while protease digestion in the presence of urea at room temperature alleviates generation of peptides derived from incomplete digestion and nonspecific cleavage by endoproteinase Glu-C. Peptide maps generated using the optimized procedures contain fewer peptide peaks with higher recovery. Elimination of incomplete digestion, which generates fewer larger, insoluble peptides, substantially extends the life of reverse-phase columns. The optimized method reproducibly produced peptide maps suitable for routine analysis. Peptide map analysis is an important analytical technique widely used to verify protein primary structures. The method is capable of specifically detecting and quantifying structural alterations in recombinant proteins, such as those derived from N-terminal blockage (1,2), oxidation (3), proteolysis (4), or amino acid sub-' To whom correspondence should be addressed.
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stitutions (5) (6) (7) . In a quality control setting, it is routinely employed as an identity test to confirm structural integrity of a recombinant protein compared to a wellcharacterized standard (8) (9) (10) .
A number of protein digests, after complete proteolytic cleavage of protein substrates, are quite soluble in regular aqueous buffers and can be readily used for development of peptide maps by high-performance liquid chromatography (HPLC).2 However, it is not surprising that another class of protein substrates, which frequently contain compact disulfide and tertiary structures, may be less digestible due to their inherent resistance to proteases. Frequently, the occurrence of incomplete digestion has led to the generation of less soluble and larger peptide fragments which tend to bind irreversibly to the column packing material and quickly degrade column performance. As a result, analysis of such peptide digests on a routine basis has been difficult. The proteolytic digest of recombinant methionyl human G-CSF (r-metHuG-CSF ), a therapeutic used to treat neutropenic patients in a number of clinical settings (11) , exhibits some of these undesirable characteristics. In order to develop a routine method suitable for r-metHuG-CSF peptide map analysis, chemical modification utilizing reduction and alkylation of the protein followed by endoproteinase Glu-C digestion and HPLC was employed.
We report here that peptide digests derived from reduced and alkylated r-metHuG-CSF derivatives are less soluble in aqueous buffers and that the peptide maps 2 Abbreviations used: Cys(Cm), S-carboxymethylcysteine; CV, coefficient of variation; DTT, dithiothreitol; GdnHCI, RP-HPLC, reverse-phase high-performance liquid chromatography; guanidine hydrochloric acid; IAA, iodoacetic acid; PTH, phenylthiohydantoin; r-metHuG-CSF, recombinant methionyl human granulocyte colony stimulating factor; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TFA, trifluoroacetic acid. 135 generated are complex, containing a number of peptide peaks derived from nonspecific proteolytic cleavages and incomplete digestion by Staphylococcus aureus V8 protease. A side reaction occurring at higher DTT and iodoacetate concentrations was also found to produce partial carboxymethylation of every methionine residue, which has generated many distinct peptide peaks of identical sequences. Optimization of the procedures eliminates these problems and generates simpler and higher quality peptide maps for routine analysis. The new method generated lower levels of the larger, less soluble peptide fragments and dramatically extended the life of the HPLC column.
MATERIALS AND METHODS

Materials
Escherichia coli-produced r-metHuG-CSF was purified according to methods described previously (12) . The recombinant molecule contains 175 amino acids, including an N-terminal methionine at position 1. Three r-metHuG-CSF analogs, r-metHuG-CSF [G1u12.21 -*-Gin], r-metHuG-CSF [Met127 -k Leu], and r-metHuG-CSF [Met 127.1sa ---*-Leu], were prepared by site-directed mutagenesis according to methods described previously (13) . Endoproteinase Glu-C, isolated from S. aureus (V8 strain), was purchased from ICN ImmunoBiologicals. Iodoacetic acid was from Sigma Chemical Co. and was crystallized twice in petroleum ether prior to use. HPLC solvents and water were purchased from Burdick and Jackson. Sequencing reagents and solvents were from Applied Biosystems and Hewlett Packard.
S-Carboxymethylation and Protease Digestion of r-metHuG-CSF
Method A. A 1.0-mg sample of r-metHuG-CSF was dried down by Speed Vac and reconstituted in 1.0 ml of 0.2 M NaHCO, , pH 8.4, or 0.3 M Tris-HCI, pH 8.4, containing 6.0 M GdnHC1. The solution was then incubated at 37°C. After 15 min, DTT was added at a molar DTTto-protein ratio of 200:1 (10.6 kilvI) and the solution was incubated for 1 h at 37°C. Iodoacetic acid (IAA) was then added at a molar IAA-to-DTT ratio of 10:1 (106 µm) and the incubation continued for 30 min at 37°C under nitrogen. The pH was adjusted to 8.4 ± 0.1 if needed, using 50 mm NaOH. To terminate the reaction, 10 pl of [3-mercaptoethanol was added to the reaction mixture, which was then incubated for another 10 min at 37°C. The S-carboxymethylated sample was subsequently dialyzed against 2.5% NH4HCO3, dried, and reconstituted in 500 Al of 0.1 M NH4HCO3 . SV8 protease was added at an enzyme-to-substrate ratio of 1:30. The digestion proceeded for 18 h at 37°C.
Method B. A 1.0-mg sample of r-metHuG-CSF was dried down by Speed Vac and reconstituted in 1.0 ml of 0.3 M Tris-HC1, pH 8.4, containing 6.0 M GdnHCI. The solution was then incubated at 37°C. After 15 min DTT was added at a molar DTT-to-protein ratio of 100:1 (5.3 µN) and the reaction was carried out for 15 min at 37°C. IAA was then added at a molar IAA-to-DTT ratio of 2:1 (10.6 gm) and the incubation continued for 20 min at 37°C under nitrogen. The reaction was quenched by the addition of 1 ill of 0-mercaptoethanol. The S-carboxymethylated sample was desalted using a PD-10 Sephadex G-25 column (Pharmacia) equilibrated with 0.1 M Tris base, pH 7.8, containing 2 M urea. The sample can also be desalted using Quick Spin Sephadex G-25 columns (Boehringer Mannheim) preequilibrated with the same buffer described above. The desalting step was performed according to the manufacturer's recommendations. The concentration of desalted samples was determined by absorbance at 280 nm (absorbance = 0.86 at 1 mg/ml). Purified samples were then diluted to 0.5 mg/ml and SV8 protease was added at an enzyme-tosubstrate ratio of 1:25. The digestion proceeded for 26 h at 25°C.
Reverse-Phase HPLC Peptide Mapping
An aliquot of the digestion mixture was injected onto a C4 (Vydac, 0.46 X 25 cm, 300 A) reverse-phase column. Peptide maps were developed by a linear gradient of acetonitrile in 0.1% TFA using an HP1090M liquid chromatograph equipped with a diode array detector and an HP work station for data collection and processing. The mobile phases used include solvent A (0.1% TFA) and solvent B (TFA:F120:CH3CN, 0.1:9.9:90). The column was initially equilibrated at 3% B at a flow rate of 0.8 ml /min. The separation was performed by a linear gradient of 3% B to 30% B for 40 min, 30% B to 55% B for 60 min, 55% B to 55% B for 10 min, and 55% B to 80% B for 5 min and by isocratic elution at 80% B for 10 min.
Sequence Analysis
Sequence analysis of peptides (14) was performed on an automated protein sequencer (Applied Biosystems Model 477A or Hewlett Packard Model G1000A). The resulting PTH amino acids released from each degradation cycle were analyzed by narrow-bore HPLC according to procedures recommended by the manufacturers.
Mass Spectrometry
Mass spectrometric analysis was performed on a Sciex ion-spray API III mass spectrometer. Samples to be analyzed were concentrated to dryness in a polypropylene microcentrifuge tube, reconstituted in 0.1% TFA in 50% aqueous acetonitrile, and introduced by a flow injection at 40 pi per minute.
Nomenclature of Peptides
SV8 protease-derived peptides shown in Fig. 2 were numbered according to their RP-HPLC elution order. In Table 1 they are cross-referenced to the peptides shown in Figs. 1 and 5 , in which the peptides are designated with an "S" followed by a number according to their respective sequence positions. For example, S1 is the N-terminal peptide, S2 is the second peptide following Si, and S11 is the C-terminal peptide. Incomplete proteolytic cleavage would generate peptide fragments such as S3-S4, S8-S9, or S7-S8-S9. RESULTS 
AND DISCUSSION
Peptide Mapping of r-metHuG-CSF
Endoproteinase Glu-C, capable of cleaving glutamyl and aspartyl peptide bonds (15) , was selected for the proteolytic digestion of r-metHuG-CSF. Since both Glu and Asp are evenly distributed along the polypeptide sequence of r-metHuG-CSF, the enzymatic cleavages at peptide bonds for the nine glutamyl (at positions 20, 34, 46, 47, 94, 99, 123, 124, and 163) and four aspartyl residues (at positions 28, 105, 110, and 113) are expected to generate a moderate number of small peptides of reasonable size for subsequent HPLC analysis. Table 1 lists peptides expected from specific and nonspecific proteolytic cleavages and their respective sequence positions and sequences. Initially, native r-metHuG-CSF (0.5 mg/ml) in the absence of denaturants was subjected to endoproteinase Glu-C digestion (1:25 enzyme to substrate ratio) in 0.1 M Tris-HCI, pH 7.8, at both 25 and 37°C. As clearly shown in Fig. 1A (chromatogram a), in the absence of urea only a small fraction of peptides in the digest produced at room temperature was recovered by HPLC analysis. The peak at approximately 117 min is the major larger fragment (an N-terminal peptide, S1-S2-S3-S4 from amino acid 1-93) recovered from the map. However, a major portion of the protein digest not recoverable on the map consists of larger fragments (Mr >6500) and undigested sample as demonstrated by SDS-PAGE shown in Fig. 1B (lane 2) . Interestingly, native r-metHuG-CSF digest produced at 37°C generates more peptides with higher recovery yield, as shown in Fig. 1A , chromatogram b. As clearly demonstrated by SDS-PAGE (Fig. 1B, lane 6 ), the digestion is more complete at 37°C in the absence of urea. However, under such conditions, two nonspecific cleavages, occurring at Ala-142 and Ser-156, generate peptides B and C (LGM-APALQTPQGAMPAFA and SAFQRRAGGVLVAS, respectively). Peptide A (FAATTIWQQMEE) is generated from the cleavage at Asp-132. Nonetheless, peak heights for the N-terminal peptide S1 and peptide S10 are relatively small and the disulfide-containing (Cys"-Cys') peptide S4 is also missing (see Table 1 ), indicating that these peptides were not well recovered. Nonspecific cleavage of r-metHuG-CSF at Ser-143 with the protease was reported by Layton et al. (16) . They were also unable to recover peptide S4. The small peaks eluting after S1 are not sequenceable.
As illustrated in Fig. lA (chromatogram c), the addition of 2 M urea to the digestion buffer (0.1 M Tris-HCI, pH 7.8) at 25°C also enhances the proteolytic digestion of r-metHuG-CSF, although the recovery for most peptides remains low (see below). Peptides S2 and S3 near the N-terminus together with C-terminal peptides S10 and S11 had increased peak height compared to the heights in chromatogram a. The nonspecific cleavages at Ala-142 and Ser-156 as seen at 37°C were not observed. The incompletely digested N-terminal peptide S1-S2-S3-S4 had also dramatically diminished; however, peptides S1 and S4 remain unrecovered. This result seems to suggest that addition of urea in the digestion buffer facilitates sample solubility and increases the accessibility of r-metHuG-CSF to proteolytic cleavages (see The above observations thus indicate that the general approach to peptide map analysis of r-metHuG-CSF has several difficulties and that other optimized procedures, such as digestion of chemically modified G-CSF derivative, must be developed.
Peptide Mapping of Cys(Cm)-r-metHuG-CSF Derivative
In performing peptide mapping of carboxymethylated r-metHuG-CSF derivative, [Cys(Cm)-r-metHuG-CSF], we initially employed method A, which includes denaturation of protein followed by reduction, alkylation, and desalting by dialysis. When the sample is dialyzed into 0.1 M NE 4 -1C%, the resulting derivative is denatured, unfolded, and not completely soluble. This heterogeneous sample suspension was then subjected to endoproteinase Glu-C digestion at 37°C. As shown in Fig. 2 , the HPLC separation of the digest produced by this procedure unexpectedly produces a complex map including a number of major peptide peaks, more than 10 minor peaks, and some larger incompletely digested fragments (>100 min retention time). In control experiments substrate concentrations were varied from 2 to 0.25 mg/ml for protease digestion, and the HPLC profiles generated remained unchanged and complex, indicating that substrate concentration did not affect the behavior of these digests. We recovered a total of 28 peptides from the map shown in Fig. 2 and further ana- Fig. 2 and Fig. 5 for details. Each peptide sequence was confirmed by direct sequence analysis and the peptide length for longer peptides was verified by ion-spray mass spectrometric analysis.
h Assigned sequence (see Fig. 5 ) refers to peptides found in the map produced from method A. lyzed their structures by automatic sequence determination and ion-spray mass spectrometry analysis. Table 1 summarizes the results of the analyses, the assignment of peptide sequence, and the detection of possible structural modifications. The major and minor peptide peaks plus several larger fragments were clearly assigned along the rmetHuG-CSF sequence (17) . The overall recovery of peptides, based on the area of peak integration, is much higher than that from digestion of the native protein with or without the addition of urea (see Fig. 1 ). However, under the digestion conditions described in method A, we have observed several difficulties associated with the maps. Small fractions of nonspecific cleavages at Pro-3, Ser-9, Gln-12, and Ser-143 had appeared. The nonspecific cleavages resulted in the generation of peptides 4, 5, 7, 10, and 11. Incomplete cleavage at Glu-47, Glu-94, Asp-110, and Glu-163 resulted in the generation of extra peptides such as peptides 12, 23, 24, 26, and 27. Third, incomplete digestion also resulted in the formation of precipitates and generated larger fragments (Fig. 2, peak 28 ) that seemed to be retained on the reverse-phase columns. We experienced a dramatic reduction in HPLC column efficiency and resolution after the column was exposed to the digests derived from method A. Moreover, all of the Met-containing peptides (peptides 5, 12, 16, 18, and 23) were surprisingly found to elute at several positions on the same map. As shown in Table 1 , several peptides appearing at different elution times were indistinguishable by sequencing; that is, peptides 7 and 14 were indistinguishable from peptides 5 and 16, respectively; peptide 9 was indistinguishable from peptide 12; peptide 18 was equivalent to peptides 13, 15, and 17; and peptides 20, 21, and 22 were indistinguishable by sequence analysis from peptide 23. Characterization of these peptides is described below.
S-Carboxymethylation of Methionines
The earlier-eluting peptides, 7, 9, 13, 14, 15, 17, 20, 21, and 22, were found to have a lower sequencing yield for PTH-Met; otherwise, no structural difference was evident from sequence analysis using Edman chemistry (see Table 1 ). These peptides were further characterized by ion-spray mass spectrometry. Figure 3 demonstrates a typical mass spectrometric spectrum for peptide 14. Two series of doubly and triply charged ions were observed, one corresponding to an average mass of 2249.0 and the other to 2142.0. In comparison to the average mass for peptide 16 (2190.6), differences of 58.4 from the mass of 2249.0 and of 48.6 from the mass of 2142.0 were found for peptide 14. These mass differences suggest that peptide 14 contains an S-carboxymethylated Met (mass difference = 58) or a decomposed derivative of S-carboxymethylated Met (mass difference = 48) at its N-terminus. This result clearly confirms that peptide 14 is derived from peptide 16 after S-carboxymethylation of the N-terminal Met. Table 1 for sequence).
peptide derived from further chemical degradation of the S-carhoxymethylated peptide by sample handling during HPLC or mass spectrometric analysis. The Scarboxymethyl methionine (compound II, 58 mass units more than methionine), after exposure to acid in RP-HPLC or during mass spectrometric analysis, may be hydrolyzed to become homoserine (i.e., the elimination of S-methyl, carboxymethyl sulfonium side chain), which is then dehydrated to form compound III. However, it should be noted that a respective PTH amino acid derivative for III was clearly not detected during sequence analysis of the modified peptides, and this structure should thus be considered hypothetical. Further analyses of peptides 13, 15, 17, 20, 21 , and 22 revealed that the two methionines in these peptides have been partially or completely modified by iodoacetate to form carboxymethyl methionine derivatives. Both peptides 13 and 20 have two carboxymethylated methionines, while peptides 15, 17, 21, and 22 have only one carboxymethylated methionine. The site of modification can be clearly detected by the significant decrease in the recovery of PTH-Met during sequence analysis of the modified peptides. Other evidence from site-directed mutagenesis studies also verified the HPLC elution order for these partially modified peptides on the peptide map (data not shown). Carboxymethylation of methionines in proteins or peptides has been postulated previously (18) and has been specifically used to isolate methionine-containing peptides after thiolysis at lower pH (19) .
Structural characterization of the isolated peptides described above suggests that incomplete cleavage, nonspecific cleavage, and Met carboxymethylation all con- peak area of modified peptide X 100. peak areas of modified plus unmodified peptides tribute to the complexity of the r-metHuG-CSF peptide map shown in Fig. 2 . In order to generate normal and reliable maps, we proceeded with further evaluation and careful optimization of the experimental conditions.
Optimization of Carboxymethylation and Proteolytic Digestion
The first attempt at optimization was to eliminate carboxymethylation of methionine during reduction and alkylation. Previously reported conditions for a complete reduction of protein disulfides with thiols followed by alkylation with iodoacetate or iodoacetamide varied from protein to protein (19) (20) (21) . In our studies, the concentrations of thiol (DTT) and alkylation agent (IAA) used in method A were fixed at 10.6 ALM (DTT-tototal S-S ratio, 100:1) and 106 µM (IAA-to-DTT ratio, 10:1), respectively. Under such conditions and as shown in Table 2 and Fig. 2 , approximately 50% of the Metcontaining peptides were surprisingly found to be carboxymethylated at all of the Met residues in our experiments. In further experiments, we studied the effect of DTT and IAA concentrations on both Cys and Met modifications. As shown in Table 2 , when DTT concentration is reduced to 5.3 Am and IAA to 53 µm at 1 mg/ml protein concentration, the Met modification is reduced to a level below 30%, only half of that observed in Fig. 2 . In this experiment, the IAA-to-DTT ratio is maintained at 10:1 but with IAA concentration kept at half of the concentration used in the experiment shown in Fig. 2 . As summarized in Table 2 , further experiments showed that complete elimination of Met carboxymethylation can be achieved by further reduction in the iodoacetate concentration to 10.6 or 5.3 Am (i.e., IAA-to-DTT ratio of 2:1 or 1:1). In these experiments, the protein and DTT concentrations were kept at a DTT-to-disulfide ratio of 50:1 to ensure complete reduction of disulfide bonds. We found that a further decrease in DTT concentration leads to incomplete reduction of disulfide bonds. At an IAA-to-DTT ratio of 2:1, IAA alkylation for both reduced G-CSF and DTT is stoichiometric (noting that DTT has two sulfhydryls). Thus, there is no excess IAA available for Met carboxymethylation. At an IAA-to-DTT ratio of 1:1, Met modification was also not detected, but incomplete alkylation of reduced G-CSF was clearly detected at a level approximately 5-10% of that of the modified sample by reverse-phase HPLC (data not shown). The above carboxymethylation experiments thus reveal that an IAA-to-DTT ratio of 2:1 allows the complete carboxymethylation of cysteines and produces no Met modification at 37°C at a protein concentration of 1 mg/ml.
We also evaluated buffer exchange procedures for removing salt and reagent from the carboxymethylation sample solution prior to proteolytic digestion. Dialysis of the sample was excluded since recovery of the modified derivative in method A has been variable (data not shown). Reconstitution of samples in 2 M urea buffer after concentration by Centricon-10 centrifugation resulted in drastic loss of sample in the membrane (10-30% recovery). We found that desalting samples through a small desalting column gave the highest recovery. When the reaction sample was desalted in a Pharmacia fast-desalting column on an FPLC system, an 85-95% yield as determined by 280-nm absorbance was consistently achieved. A reasonably good yield (80-90%) was also obtained with Quick-Spin Sephadex G-25 protein columns. Desalted samples obtained from these two procedures yielded comparable peptide maps after SV8 digestion and HPLC.
Further optimization of the procedures suggested that 2 M urea is the minimal concentration at which the r-metHuG-CSF derivative remains completely soluble after buffer exchange. The optimal conditions for SV8 protease digestion were found to be 25°C and 26 h. Elevated temperatures tended to cause urea inactivation of the protease and precipitation of otherwise soluble digests. Shorter incubation time (<22 h) seemed to generate more incompletely cleaved peptides. Under the final optimized conditions, a low ratio of DTT to iodoacetate, 2 M urea in the digestion buffer, and a column desalting step were thus introduced in method B (for details, see Materials and Methods). The digestion was carried out at 25°C for 26 h. As illustrated in Fig. 5 , a total of 10 distinct peaks (excluding peptides S3-S4, S6-S7-S8-S9, S3-S4-S5, and S4-S5) were identified. The corresponding sequences for these peptides are listed in Table 1. The numbers of peptides derived from nonspecific cleavages and larger fragments from incomplete cleavages and those derived from aspartyl cleavage are greatly reduced. It should be noted that peptide S5 is clearly recovered on the map in Fig. 5 but not on the map derived from method A (Fig. 2) . Peptides S6-S7-S8-S9, S7-S8-S9, and S8-S9 contain Glu-124 at their C-termini and represent fragments derived from incomplete cleavages at Asp-105, Asp-110, and Asp-113. Peptides S5 (GISPE) and S8 (VAD), which are hydrophilic and small, are not retained in the C-4 column. Peptide S8 was also recovered in very low yield due to the low cleavage rate for Asp-113 bond. Endoproteinase Glu-C exhibits lower cleavage rates on Glu-47 and Glu-94; as a result, peptides S3-S4, S3-S4-S5, and S4-S5 are still detected in small quantities. It should also be noted that all of the peaks derived from carboxymethylation of methionines have disappeared.
In method B, the use of urea (2 M) in the digestion buffer greatly increased the solubility of the G-CSF derivative and facilitated complete proteolytic digestion. Urea seemed to enhance the digestion efficiency and facilitated elimination of most of the nonspecific and incomplete cleavages seen on the maps derived from method A. As expected, the mild reduction and alkylation conditions used in the method prevented carboxymethylation of all of the methionine-containing peptides. Moreover, more than 100-200 injections of the digests could be obtained on a single reverse-phase column, a substantial increase in column usage over that observed in previous experiments.
Validation of Method B
To verify that method B could be used as a routine analytical testing method, the accuracy and reproducibility of the method were evaluated. Three aliquots of one lot of r-metHuG-CSF were separately analyzed by peptide mapping. The assays were performed in parallel under identical conditions. The coefficient of variance (CV) for peptide retention times ranged from 0.02 to 0.20% (average = 0.07%). As a general observation, though, elution times for earlier-eluting peptides (such as S2 and S5) were less accurate than those for more hydrophobic peptides.
When the N-terminal peptide Si was selected for normalization of the peak area obtained for each peptide from different maps, the CV for peptide peak area averaged 7.58% for group I peptides (i.e., peptides Si, S2, S3, S4, S5, S6, S10, and S11), derived mainly from a complete digestion of the protein. The CV for group II peptides containing four incompletely digested peptides (i.e., S3-S4, S4-S5, S8-S9, and S8-S9-S10) was much higher (38.32% average). It is clear that variation in peak area is greater for peptides with smaller peak height (or peak area) such as S6 ( -20%) and the group II peptides derived from incomplete cleavages.
The linear response of the assay has been examined for injections ranging from 12.5 to 125 ptg of the digest. The coefficient of variance is relatively high for each peptide (correlation coefficient = 1.000), except peptide S4 (correlation coefficient = 0.992) due to the interference of the coeluting peptide S6-S7-S8-S9 at larger injection amounts.
Several r-metHuG-CSF variants were prepared by site-directed mutagenesis to validate that this peptide mapping procedure can detect structural alterations in r-metHuG-CSF. Figure 6A the peptide maps of the wild-type sample and of the two variant forms, Met127
Leu analog and Met1273" Leu analog. Substitution of the two methionines for Leu clearly caused a shift to a longer retention time for peptide S10 due to an increase in hydrophobicity. A deamidation analog (G1n12•21 Glu) of r-metHuG-CSF was also subjected to peptide mapping. Clearly, the alterations caused by deamidation of the two glutamines can be detected on the map shown in Fig. 6B . Peptide S1 is the N-terminal peptide of the protein (from Met-1 to Glu-20) and peptide S2 contains peptide sequence following peptide S1 (from Gln-21 to Glu-33). Deamidation of Gln-12 and Gln-21 results in the disappearance of peptides S1 and S2. However, three extra peptides, N1 , N2 and N3 , were eluted at distinct retention times. They were produced by SV8 protease at the extra glutamyl cleavage sites generated by mutation. N1 is the peptide from Met-1 to Glu-12, N2 is from Ser-13 to Glu-21, and N3 is from Val-22 to Glu-33. When compared to N3, peptide S2 contains an extra Gln at its N-terminus and elutes about 0.2 min later than peptide N3. Modified peptides derived from digestion of recombinant G-CSF containing N-terminal formyl methionine (1) or other modifications are also different from the unmodified peptides in their respective retention times in the peptide maps (data not shown).
When the wild-type molecule is mixed with various amounts of Met127338 Leu analog (0 to 40%) for peptide map analysis, the variant peptide can then be detected and quantified. The quantification of the variant peptide in the mixture is linear over the theoretical value and the detection level is below 2.5% at a 50-14 sample load. This detection limit can also be verified by detection of other modified peptides derived from posttranslational modification and site-directed mutagenesis.
Conclusion
Difficulties in peptide map analysis of native rmetHuG-CSF have arisen as a result of incomplete digestion of the nondenatured protein, whereas peptide mapping derived from digestion of the insoluble Cys(Cm)-r-metHuG-CSF preparation has resulted in other analytical difficulties, such as incomplete and nonspecific cleavages due to poor solubility of the digest. Moreover, unintentional methionine carboxymethylation of r-metHuG-CSF has generated extra peptide peaks that further deteriorate the quality of the map. Methionine modification together with incomplete cleavage also resulted in the generation of maps with less reproducibility, which caused a decrease in accuracy of peak quantitation and made validation difficult. Optimized conditions for alkylation and endoproteinase Glu-C digestion of r-metHuG-CSF were identified. Digestion at 25°C in 2 M urea was carried out to prevent substrate aggregation and to minimize urea inactivation of SV8 protease. These modifications have substantially eliminated the difficulties associated with the maps generated using other described procedures. The elimination of undesired peptides (nonspecifically cleaved and unintentionally modified) has aided in the development of representative and reproducible maps for routine analysis. Moreover, the removal of larger, insoluble peptides has dramatically extended the utility of reverse-phase columns. The method has also been evaluated for reproducibility, accuracy, and sensitivity, and its utility in detecting altered peptides derived from structural alterations in r-metHuG-CSF has been proved. Approaches similar to this should be applicable to a number of other disulfide-containing cytokines or growth factors that are resistant to digestion in their native state and exhibit poor solubility after proteolytic digestion.
